New drug DD01 shows promise for fatty liver in early trial
NCT ID NCT06410924
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This Phase 2 trial tested a drug called DD01 in 67 overweight or obese adults with a type of fatty liver disease (MASLD/MASH). The goal was to see if DD01 could safely reduce liver fat by at least 30% over 48 weeks compared to a placebo. The study is completed, and results will show whether DD01 is a potential treatment for this common liver condition.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
DD01 (a dual GLP-1 and glucagon receptor agonist)
What this could lead to
If successful, DD01 could offer a new treatment option to reduce liver fat and improve liver health in people with MASLD/MASH.
What could go wrong
This is a small Phase 2 trial with only 67 participants, so results may not apply to everyone. The drug may cause side effects or fail to show clear benefit over placebo.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NAFLD are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Summit Research Site
Maitland, Florida, 92751, United States
-
Summit Research Site
Monroe, Louisiana, 71201, United States
-
Summit Research Site
West Monroe, Louisiana, 71291, United States
-
Summit Research Site
Kansas City, Missouri, 64131, United States
-
Summit Research Site
Austin, Texas, 78757, United States
-
Summit Research Site
Bellaire, Texas, 77401, United States
-
Summit Research Site
Brownsville, Texas, 78520, United States
-
Summit Research Site
Corpus Christi, Texas, 78404, United States
-
Summit Research Site
Edinburg, Texas, 78539, United States
-
Summit Research Site
Georgetown, Texas, 78626, United States
-
Summit Research Site
San Antonio, Texas, 78222, United States
-
Summit Research Site
San Antonio, Texas, 78229, United States